Tu R, Ma J, Chen Y, Kang Y, Ren D, Cai Z
Cell Death Dis. 2024; 15(10):749.
PMID: 39406703
PMC: 11482519.
DOI: 10.1038/s41419-024-07136-0.
Bantug G, Hess C
Nat Immunol. 2023; 24(12):2008-2020.
PMID: 38012409
DOI: 10.1038/s41590-023-01675-y.
Shafqat A, Omer M, Ahmed E, Mushtaq A, Ijaz E, Ahmed Z
Front Immunol. 2023; 14:1200941.
PMID: 37520562
PMC: 10374407.
DOI: 10.3389/fimmu.2023.1200941.
Shirole N, Kaelin Jr W
Hematol Oncol Clin North Am. 2023; 37(5):809-825.
PMID: 37270382
PMC: 11315268.
DOI: 10.1016/j.hoc.2023.04.011.
Rose J, Akdogan-Ozdilek B, Rahmberg A, Powell M, Hicks S, Scharer C
Commun Biol. 2023; 6(1):363.
PMID: 37012418
PMC: 10070634.
DOI: 10.1038/s42003-023-04747-9.
Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance.
Mazumder S, Higgins P, Samarakoon R
Cancers (Basel). 2023; 15(4).
PMID: 36831657
PMC: 9953937.
DOI: 10.3390/cancers15041316.
Neurological applications of belzutifan in von Hippel-Lindau disease.
Zhang Y, Nguyen C, Zhang N, Fink N, John J, Venkatesh O
Neuro Oncol. 2022; 25(5):827-838.
PMID: 36215167
PMC: 10158112.
DOI: 10.1093/neuonc/noac234.
Mutation of the proline P81 into a serine modifies the tumour suppressor function of the von Hippel-Lindau gene in the ccRCC.
Chesnel F, Jullion E, Delalande O, Couturier A, Alusse A, Le Goff X
Br J Cancer. 2022; 127(11):1954-1962.
PMID: 36175619
PMC: 9681884.
DOI: 10.1038/s41416-022-01985-2.
The convergence of tumor suppressors on the type I interferon pathway in clear cell renal cell carcinoma and its therapeutic implications.
Langbein L, El Hajjar R, Kim W, Yang H
Am J Physiol Cell Physiol. 2022; 323(5):C1417-C1429.
PMID: 36154696
PMC: 9662805.
DOI: 10.1152/ajpcell.00255.2022.
Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer.
Kaelin Jr W
J Clin Invest. 2022; 132(18).
PMID: 36106637
PMC: 9479583.
DOI: 10.1172/JCI162480.
Integrative Analysis of the Genomic and Immune Microenvironment Characteristics Associated With Clear Cell Renal Cell Carcinoma Progression: Implications for Prognosis and Immunotherapy.
Lin E, Zhu P, Ye C, Huang M, Liu X, Tian K
Front Immunol. 2022; 13:830220.
PMID: 35677048
PMC: 9168804.
DOI: 10.3389/fimmu.2022.830220.
Hypoxia-Reoxygenation Couples 3βHSD1 Enzyme and Cofactor Upregulation to Facilitate Androgen Biosynthesis and Hormone Therapy Resistance in Prostate Cancer.
Qin L, Chung Y, Berk M, Naelitz B, Zhu Z, Klein E
Cancer Res. 2022; 82(13):2417-2430.
PMID: 35536859
PMC: 9256813.
DOI: 10.1158/0008-5472.CAN-21-4256.
RGMQL: scalable and interoperable computing of heterogeneous omics big data and metadata in R/Bioconductor.
Pallotta S, Cascianelli S, Masseroli M
BMC Bioinformatics. 2022; 23(1):123.
PMID: 35392801
PMC: 8991469.
DOI: 10.1186/s12859-022-04648-4.
Sensitivity of mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway.
Stransky L, Vigeant S, Huang B, West D, Denize T, Walton E
Proc Natl Acad Sci U S A. 2022; 119(14):e2120403119.
PMID: 35357972
PMC: 9168943.
DOI: 10.1073/pnas.2120403119.
Targeting HIF-2α in the Tumor Microenvironment: Redefining the Role of HIF-2α for Solid Cancer Therapy.
Davis L, Recktenwald M, Hutt E, Fuller S, Briggs M, Goel A
Cancers (Basel). 2022; 14(5).
PMID: 35267567
PMC: 8909461.
DOI: 10.3390/cancers14051259.
iASPP is essential for HIF-1α stabilization to promote angiogenesis and glycolysis via attenuating VHL-mediated protein degradation.
Zhao D, Zheng S, Wang X, Liu H, Zhao K, Li L
Oncogene. 2022; 41(13):1944-1958.
PMID: 35169254
DOI: 10.1038/s41388-022-02234-9.
Hypoxia-Inducible Factors in Cancer.
Kim L, Simon M
Cancer Res. 2022; 82(2):195-196.
PMID: 35042744
PMC: 9326459.
DOI: 10.1158/0008-5472.CAN-21-3780.
Playing the Devil's Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? - ie Strategies to Revert Resistance to mTOR Inhibitors.
Pezzicoli G, Filoni E, Gernone A, Cosmai L, Rizzo M, Porta C
Cancer Manag Res. 2021; 13:7623-7636.
PMID: 34675658
PMC: 8500499.
DOI: 10.2147/CMAR.S267220.
A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer.
Geynisman D, Maranchie J, Ball M, Bratslavsky G, Singer E
Urol Oncol. 2021; 39(9):548-560.
PMID: 34092483
PMC: 9030590.
DOI: 10.1016/j.urolonc.2021.04.038.
Enhanced anti-angiogenic activity of novel melatonin-like agents.
Hwang S, Jung Y, Song Y, Park S, Park Y, Lee H
J Pineal Res. 2021; 71(1):e12739.
PMID: 33955074
PMC: 8365647.
DOI: 10.1111/jpi.12739.